T1	intervention 20 31	fenretinide
T2	condition 43 67	second breast malignancy
T3	eligibility 71 101	women with early breast cancer
T4	No-of-participants 343 347	2972
T5	No-of-participants 360 371	30-70 years
T6	eligibility 373 446	with surgically removed stage I breast cancer or ductal carcinoma in situ
T7	duration 462 469	5 years
T8	control 512 524	no treatment
T10	outcome-Measure 729 746	menopausal status
T11	outcome-Measure 748 779	incidence of distant metastases
T12	outcome-Measure 781 798	overall mortality
T13	outcome-Measure 804 826	tumors in other organs
T9	outcome-Measure 569 596	contralateral breast cancer
T14	outcome-Measure 600 625	ipsilateral breast cancer
T16	outcome 1194 1270	interaction was detected between fenretinide treatment and menopausal status
T17	outcome 1777 1922	no statistically significant differences between the two arms in tumors in other organs, incidence of distant metastasis, and all-cause mortality
T15	outcome 1021 1149	no statistically significant differences in the occurrence of contralateral breast cancer (P =.642) or ipsilateral breast cancer
